BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases
BD (NYSE: BDX) and Quest Diagnostics (NYSE: DGX) have announced a global collaboration agreement to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. This partnership aims to provide the pharmaceutical industry with an end-to-end solution for CDx development, ranging from exploratory panel development to FDA-approved diagnostic kit distribution.
The collaboration leverages BD's expertise in flow cytometry and Quest's proficiency in biomarker and assay development. Flow cytometry, an established laboratory technology, can rapidly analyze individual cells, potentially improving patient management and clinical outcomes. This initiative is expected to advance personalized medicine and potentially reduce healthcare costs by enabling more precise treatment selection.
BD (NYSE: BDX) e Quest Diagnostics (NYSE: DGX) hanno annunciato un accordo di collaborazione globale per sviluppare, produrre e commercializzare diagnostica companion basata sulla citometria a flusso (CDx) per il cancro e altre malattie. Questa partnership mira a fornire all'industria farmaceutica una soluzione completa per lo sviluppo di CDx, che va dallo sviluppo di pannelli esplorativi alla distribuzione di kit diagnostici approvati dalla FDA.
La collaborazione sfrutta l'esperienza di BD nella citometria a flusso e la competenza di Quest nello sviluppo di biomarcatori e saggi. La citometria a flusso, una tecnologia di laboratorio consolidata, può analizzare rapidamente cellule singole, migliorando potenzialmente la gestione dei pazienti e gli esiti clinici. Questa iniziativa si prevede favorisca la medicina personalizzata e potrebbe ridurre i costi sanitari permettendo una selezione di trattamenti più precisa.
BD (NYSE: BDX) y Quest Diagnostics (NYSE: DGX) han anunciado un acuerdo de colaboración global para desarrollar, fabricar y comercializar diagnósticos acompañantes basados en citometría de flujo (CDx) para el cáncer y otras enfermedades. Esta asociación tiene como objetivo proporcionar a la industria farmacéutica una solución integral para el desarrollo de CDx, que abarca desde el desarrollo de paneles exploratorios hasta la distribución de kits diagnósticos aprobados por la FDA.
La colaboración aprovecha la experiencia de BD en citometría de flujo y la competencia de Quest en el desarrollo de biomarcadores y ensayos. La citometría de flujo, una tecnología de laboratorio establecida, puede analizar rápidamente células individuales, mejorando potencialmente la gestión de pacientes y los resultados clínicos. Se espera que esta iniciativa avance en la medicina personalizada y que potencialmente reduzca los costos de atención médica al permitir una selección de tratamientos más precisa.
BD(NYSE: BDX)와 Quest Diagnostics(NYSE: DGX)는 암 및 기타 질병에 대한 유세포 분석 기반 동반 진단(CDx)을 개발, 제조 및 상용화하기 위한 글로벌 협력 계약을 발표했습니다. 이 파트너십은 제약 산업에 CDx 개발을 위한 종합 솔루션을 제공하는 것을 목표로 하며, 탐색 패널 개발부터 FDA 승인 진단 키트 배포까지 포괄합니다.
이 협력은 BD의 유세포 분석 전문성과 Quest의 바이오 마커 및 분석 개발 능력을 활용합니다. 유세포 분석은 확립된 실험실 기술로, 개별 세포를 신속하게 분석하여 환자 관리와 임상 결과를 개선할 수 있습니다. 이 이니셔티브는 맞춤형 의료를 발전시키고, 보다 정밀한 치료 선택을 가능하게 하여 의료 비용을 줄일 것으로 예상됩니다.
BD (NYSE: BDX) et Quest Diagnostics (NYSE: DGX) ont annoncé un accord de collaboration mondial pour développer, fabriquer et commercialiser des diagnostics accompagnants basés sur la cytométrie en flux (CDx) pour le cancer et d'autres maladies. Ce partenariat vise à fournir à l'industrie pharmaceutique une solution complète pour le développement de CDx, allant du développement de panels exploratoires à la distribution de kits diagnostiques approuvés par la FDA.
La collaboration exploite l'expertise de BD en matière de cytométrie en flux et la compétence de Quest dans le développement de biomarqueurs et d'essais. La cytométrie en flux, une technologie de laboratoire établie, peut analyser rapidement des cellules individuelles, améliorant potentiellement la gestion des patients et les résultats cliniques. Cette initiative devrait faire avancer la médecine personnalisée et réduire potentiellement les coûts de santé en permettant une sélection de traitements plus précise.
BD (NYSE: BDX) und Quest Diagnostics (NYSE: DGX) haben eine weltweite Kooperationsvereinbarung bekannt gegeben, um auf der Durchflusszytometrie basierende Begleitdiagnostika (CDx) für Krebs und andere Krankheiten zu entwickeln, zu produzieren und zu vermarkten. Diese Partnerschaft zielt darauf ab, der Pharmaindustrie eine End-to-End-Lösung für die CDx-Entwicklung bereitzustellen, die von der Entwicklung von Erkundungspanels bis zur Verteilung von FDA-zugelassenen Diagnosetests reicht.
Die Zusammenarbeit nutzt die Expertise von BD in der Durchflusszytometrie und die Kompetenz von Quest in der Entwicklung von Biomarkern und Tests. Die Durchflusszytometrie ist eine etablierte Labortechnologie, die die schnelle Analyse einzelner Zellen ermöglicht und potenziell das Patientenmanagement und die klinischen Ergebnisse verbessert. Es wird erwartet, dass diese Initiative die personalisierte Medizin vorantreibt und möglicherweise die Gesundheitskosten senkt, indem sie eine präzisere Auswahl von Behandlungen ermöglicht.
- Global collaboration agreement to develop and commercialize companion diagnostics
- Potential to advance personalized medicine in cancer and other diseases
- Combination of BD's flow cytometry expertise with Quest's biomarker development capabilities
- Opportunity to provide end-to-end CDx solutions for the pharmaceutical industry
- Potential to improve patient outcomes and reduce healthcare costs
- None.
This collaboration between BD and Quest Diagnostics marks a significant step forward in the field of personalized medicine, particularly for cancer treatment. The focus on flow cytometry-based companion diagnostics (CDx) is especially noteworthy. Flow cytometry offers several advantages over traditional diagnostic methods:
- Rapid analysis of individual cells
- Insight into a patient's immune response
- Potential for more precise treatment selection
The partnership aims to provide an end-to-end solution for CDx development, which could streamline the process from exploratory panel development to FDA-approved diagnostic kits. This comprehensive approach may accelerate the development and adoption of new companion diagnostics, potentially leading to more targeted therapies reaching patients faster.
However, it's important to note that while flow cytometry is an established technology, its application in CDx is relatively new. The success of this venture will depend on the ability to demonstrate clear clinical utility and cost-effectiveness compared to existing diagnostic methods such as IHC, FISH, PCR and NGS.
From an investor's perspective, this collaboration could position both companies favorably in the growing personalized medicine market, estimated to reach
This strategic partnership between BD and Quest Diagnostics has the potential to create significant value for both companies. Here's why:
- Market Expansion: The global companion diagnostics market is projected to grow at a CAGR of
12.1% from 2021 to 2028. This collaboration positions both companies to capture a larger share of this expanding market. - Synergistic Capabilities: BD's expertise in flow cytometry combined with Quest's experience in biomarker development and assay validation creates a powerful offering that could differentiate them in the market.
- Revenue Diversification: For BD, this move expands its presence in the high-growth diagnostics sector, potentially offsetting slower growth in traditional medical device segments.
- Enhanced Value Proposition: Quest Diagnostics can now offer a more comprehensive solution to pharmaceutical companies, potentially increasing its attractiveness as a partner for drug development.
However, investors should be aware of potential challenges:
- Regulatory Hurdles: FDA approval for new companion diagnostics can be a lengthy and costly process.
- Competition: Other major players like Roche and Abbott are also active in this space.
- Adoption Rate: The success of this venture will depend on how quickly pharmaceutical companies and healthcare providers adopt these new flow cytometry-based CDx.
Overall, while this collaboration presents significant opportunities, its financial impact may take time to materialize fully. Investors should monitor key milestones such as successful CDx development and regulatory approvals to gauge the partnership's progress.
Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care
Together, BD and Quest will aim to provide the pharmaceutical industry with an end-to-end solution for CDx development. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
"BD has been at the forefront of flow cytometry innovation for a half-century, consistently leading advancements in this critical field," said Steve Conly, worldwide president of Biosciences at BD. "Our collaboration with Quest underscores a shared commitment to advance personalized medicine by leveraging this technology in the development of companion diagnostics to be used alongside therapeutic options for patients."
Using companion diagnostics to help select a first-line therapy for cancer patients can be critical to ensuring the best outcomes and cost savings. Today's companion diagnostic tests commonly involve technologies such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS) and imaging. Flow cytometry, an established laboratory technology now being applied in the development of companion diagnostics, can rapidly analyze and sort individual cells to enable health care providers to understand an individual's immune response and could provide insight as to how best to manage the patient to improve clinical outcomes.
"This strategic collaboration with BD will combine our expertise in developing and validating biomarkers and assays with BD's leadership in flow cytometry to offer a fully integrated solution on a larger scale," said William Finger, vice president and general manager, Pharma Services for Quest Diagnostics. "Together, we can bring novel companion diagnostics to market that will enable more precise health care, to potentially improve patient outcomes and reduce health care costs."
Through its BioPharma services business, Quest Diagnostics offers end-to-end solutions for drug development, including clinical trial lab testing, companion diagnostic development, commercialization, and post-launch surveillance. For more information, visit pharma.questdiagnostics.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
Contacts: | |
BD Media Contact: | BD Investor Contact: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations, BD | Sr. Director, Investor Relations, BD |
858.617.2361 | 201.847.6927 |
Quest Media Contact: | Quest Investor Contact: |
Jen Petrella | Shawn Bevec |
Quest Diagnostics | Quest Diagnostics |
973-520-2800 | 973-520-2900 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-quest-diagnostics-join-forces-to-develop-companion-diagnostics-for-cancer-other-diseases-302206462.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What is the purpose of the collaboration between BD (BDX) and Quest Diagnostics?
How can flow cytometry-based companion diagnostics benefit patients?
What advantages does the BD (BDX) and Quest Diagnostics collaboration offer to the pharmaceutical industry?
When was the collaboration between BD (BDX) and Quest Diagnostics announced?
